Eli Lilly Suffers Setback As Alzheimer"s Study Fails To Meet Primary Endpoint
Eli Lilly And Co (NYSE: LLY) shares were losing ground Monday following an announcement concerning the result of a Phase 2/3 study of an experimental Alzheimer's drug. 0 read more.....»»
Eli Lilly, Roche slide after Alzheimer"s drug fails to meet endpoint in study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Eli Lilly announces ANNOUNCE study of Lartruvo did not meet primary endpoints
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
read more.....»»
Eli Lilly, Incyte announce baricitinib study did not meet primary endpoint
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal
Eli Lilly & Co. and Incyte Corp. said Thursday a Phase 3 trial of rheumatoid arthritis treatment .....»»
Incyte"s Ruxolitinib Fails To Beat Placebo In Improving Mortality In Critically-Ill COVID-19 Patients
Incyte Corporation NASDAQ: INCY) announced results from the Phase 3 DEVENT study evaluating two doses of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients read more.....»»
Eli Lilly, Incyte announce BRAVE-AA2 study met primary endpoint
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
COVID-19 Convalescent Plasma Study Shows No Benefit, US NIH Stops Trial
The National Institutes of Health (NIH) has halted a trial evaluating the safety and effectiveness.....»»
Gilead, Galapagos drug fails in Phase 3 clinical study
Shares of Gilead Sciences Inc. were down 0.1% in premarket trading on Thursday, the day after the company said an experimental idiopathic pulmonary fibrosis drug it was developing with Galapagos failed a Phase 3 clinical trial. Shares o.....»»
Opiant says First patient dosed in confirmatory PK study of PNT003
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Prothena announces confirmatory Phase 3 AFFIRM-AL study of birtamimab
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Lilly says late-stage study showed combo therapy can reduce deaths and hospitalizations in COVID-19 patients
Shares of Eli Lilly & Co. were up 0.3% in premarket trading on Tuesday after the drugmaker said combining two of its experimental COVID-19 antibod.....»»
Biogen"s stock is up 5% after Lilly reports positive data from an Alzheimer"s study
Shares of Biogen Inc. gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food and Drug A.....»»
Eli Lilly to begin pragmatic study of neutralizing antibody for COVID-19
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Eli Lilly announces opening of patient enrollment for New IDEAS study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»